This post has been archived and contains information that may be out of date.
Last week, a federal district court ruled that the Department of Health and Human Services (HHS) exceeded its statutory authority when it implemented a 30% reduction to 2019 Medicare reimbursement rates — included in the federal fiscal year (FFY) 2019 outpatient prospective payment system (OPPS) final rule — for certain pharmaceutical drugs covered by the 340B Drug Pricing Program.
This content is restricted to members.
